Managed Healthcare Executive September 9, 2024
This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on currently approved FDA indications, including 36.2 million people with obesity.
About 42% of those with commercial insurance could be eligible for glucagon-like peptide 1 (GLP-1) drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. But only about 3% of adults with employer coverage had a prescription in 2022 for these medications.
The Peterson-KFF Health System Tracker estimated the clinical eligibility and use of GLP-1 drugs among adults under age 65 in the private and employer-sponsored insurance. The analysts used the 2023 National Health Interview Survey...
Today's Sponsors
Today's Sponsor